Wanling Xie

21PUBLICATIONS
244CO-AUTHORS
Molecular targetsRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

|May 07, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

|Apr 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer.

|Dec 13, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Rana R McKay, Sumanta Pal, Wanling Xie

|Jul 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.

Charlene M Mantia, Opeyemi A Jegede, David F McDermott

|Jul 02, 2025
Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.

Chris Labaki, Eddy Saad, Katrine N Madsen

Pageof 4

Frequent Collaborators

12 joint publications

Toni K Choueiri

8 joint publications

Rana R McKay

7 joint publications

David F McDermott

5 joint publications

Bradley McGregor